# Epikast

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epikast

- Industry: Software
- Headquarters: Brooklyn, US
- Website: www.epikast.com
- Total disclosed funding: $0.7M
- Latest round: Series B (Jan 22, 2026)
- Investors on record: 1

## About

Based in the US, Epikast Inc. engages in providing advanced healthcare engagement solutions, enhancing interactions between biopharma and healthcare stakeholders through innovative AI-driven tools and medically trained talent.Epikast Inc. specializes in advanced healthcare engagement solutions. Founded in 2022, the company has completed two deal to date. The firm is headquartered in the United States and was established to address the communication needs within the healthcare sector. In January 2026, Epikast Inc. raised USD 700,000 in series B funding led by Kos Biotechnology Partners..Epikast specializes in providing advanced healthcare engagement solutions through its core offerings, which include medically trained talent and proprietary AI-driven engagement tools. The company's services enhance interactions with key stakeholders in the biopharma and healthcare sectors, specifically targeting patients, physicians, and healthcare providers across the United States and Europe. Epikast's peer-to-peer engagement model is designed to drive impactful communication, reduce operational costs, and enhance product performance. The offerings facilitate real-time insights for clients, enabling them to refine their strategies and messaging based on feedback from healthcare professionals and patients. The company caters to a variety of clients, including commercial leaders, medical affairs teams, and payer executives, all seeking to improve their outreach and engagement strategies in a cost-effective manner.Epikast generates revenue primarily through partnerships and contractual agreements with biopharma and healthcare organizations. The company’s engagement model typically involves a structured pricing plan, where clients invest in tailored solutions that include access to expert teams and proprietary AI tools designed for specific healthcare outcomes. Transactions are primarily B2B, focusing on collaborations that allow organizations to enhance their communication with healthcare professionals and patients. Revenue is derived from these partnerships, which may include fixed fees for services rendered, subscription models for ongoing access to AI-driven insights, and performance-based incentives tied to the effectiveness of the engagement strategies implemented. Specific pricing plans for individual services and products are structured to meet the varying needs of their diverse clientele, ensuring flexibility and adaptability in their approach. In January 2026, Epikast Inc. USD 700,000 in series B funding led by Kos Biotechnology Partners. The company will utilize this funding to support its growth and further development of its proprietary technology platform. Future plans include the launch of new products aimed at enhancing healthcare engagement solutions. The company is also targeting expansion into additional markets within Europe and North America by 2026.

## Funding rounds

- Series B, Jan 22, 2026, $0.7M — Kos Biotechnology Partners

## Investors

- Kos Biotechnology Partners (https://capitalatlas.ai/funds/kos-biotechnology-partners) — Series B